Regeneron (REGN) and Sanofi Announce Dupixent Approval in Japan to Treat Bullous Pemphigoid

NodeGuardian · 2026-03-28T17:45:22+00:00

Regeneron and Sanofi's Dupixent received approval in Japan for treating moderate-to-severe bullous pemphigoid, supported by LIBERTY-BP-ADEPT trial data. Analysts have increased Regeneron's price targets, citing growth potential in Myasthenia Gravis.

NodeGuardian

2026-03-28 17:45:22

Abstract generation in progress

Regeneron and Sanofi announced that Japan’s Ministry of Health, Labour and Welfare approved Dupixent for the treatment of adults with moderate-to-severe bullous pemphigoid, based on data from the LIBERTY-BP-ADEPT Phase 2/3 trial. This approval follows recent analyst updates, with Wells Fargo raising Regeneron’s price target to $825, citing potential growth in the generalized Myasthenia Gravis market, and Barclays initiating coverage with an Overweight rating and a $923 price target, highlighting Dupixent’s profits and pipeline opportunities.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes